Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 59, Issue 18, Pages 1592-1597Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.03.012
Keywords
-
Categories
Funding
- Cleveland Clinic Coordinating Center for Clinical Research
- Pfizer
- AstraZeneca
- Novartis
- Roche
- Daiichi-Sankyo
- Takeda
- Sanofi-Aventis
- Resverlogix
- Eli Lilly
- Anthera
- Lipid Sciences
Ask authors/readers for more resources
Objectives The purpose of this study was to determine atheroma progression in patients with spotty calcification. Background Although extensively calcified atherosclerotic lesions have been proposed to be clinically quiescent, the presence of spotty calcification within plaque has been reported to be associated with an increased incidence of ischemic cardiovascular events. The relationship between spotty calcification and disease progression has not been investigated. Methods A total of 1,347 stable patients with angiographic coronary artery disease underwent serial evaluation of atheroma burden with intravascular ultrasound imaging. Patients with spotty calcification were identified based on the presence of lesions (1 to 4 mm in length) containing an arc of calcification of <90 degrees. Clinical characteristics and disease progression were compared between patients with spotty calcification (n = 922) and those with no calcification (n = 425). Results Patients with spotty calcification were older (age 56 years vs. 54 years; p = 0.001), more likely to be male (68% vs. 54%; p = 0.01), and have a history of diabetes mellitus (30% vs. 24%; p = 0.01) and myocardial infarction (28% vs. 20%; p = 0.004), and have lower on-treatment high-density lipoprotein cholesterol levels (48 +/- 16 mg/dl vs. 51 +/- 17 mg/dl; p = 0.001). Patients with spotty calcification demonstrated a greater percent atheroma volume (PAV) (36.0 +/- 7.6% vs. 29.0 +/- 8.5%; p < 0.001) and total atheroma volume (174.6 +/- 71.9 mm(3) vs. 133.9 +/- 64.9 mm3; p < 0.001). On serial evaluation, spotty calcification was associated with greater progression of PAV (+0.43 +/- 0.07% vs. +0.02 +/- 0.11%; p = 0.002). Although intensive low-density lipoprotein cholesterol and blood pressure lowering therapy slowed disease progression, these efficacies were attenuated in patients with spotty calcification. Conclusions The presence of spotty calcification is associated with more extensive and diffuse coronary atherosclerosis and accelerated disease progression despite use of medical therapies. (J Am Coll Cardiol 2012;59:1592-7) (c) 2012 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available